Evidence map›Paper›PMID 35543087›Full record

ArticleActa physiologica (Oxford, England)2022

Increased COX-2 after ureter obstruction attenuates fibrosis and is associated with EP

Signe S Tofteng, Line Nilsson, Amalie K Mogensen, Rikke Nørregaard, Rolf Nüsing, Mikhail Diatchikhine, Lars Lund, Claus Bistrup, Boye L Jensen, Kirsten Madsen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta physiologica (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Signe S ToftengDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-5400-4272
Line NilssonDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Amalie K MogensenDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Rikke NørregaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-0580-373X
Rolf NüsingInstitute of Clinical Pharmacology, Goethe University, Frankfurt, Germany.
Mikhail DiatchikhineDepartment of Urology, Odense University Hospital, Odense, Denmark.
Lars LundDepartment of Urology, Odense University Hospital, Odense, Denmark.
Claus BistrupDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-9280-916X
Boye L JensenDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.ORCID 0000-0001-7607-213X
Kirsten MadsenDepartment of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.ORCID 0000-0002-1427-602X
University of Southern Denmark · DKAarhus University · DKGoethe University Frankfurt · DEOdense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimCyclooxygenase-2 (COX-2) activity protects against oxidative stress and apoptosis early in experimental kidney injury. The present study was designed to test the hypothesis that COX-2 activity attenuates fibrosis and preserves microvasculature in injured kidney. The murine unilateral ureteral-obstruction (UUO) model of kidney fibrosis was employed and compared with human nephrectomy tissue with and without chronic hydronephrosis.

methodsFibrosis and angiogenic markers were quantified in kidney tissue from wild-type and COX-2

resultsCOX-2 immunosignal was observed in interstitial fibroblasts at baseline and after UUO. Fibronectin, collagen I, III, alpha-smooth muscle actin, and fibroblast specific protein-1 mRNAs increased significantly more after UUO in COX-2

conclusionCOX-2 protects in the early phase against obstruction-induced fibrosis and maintains angiogenic factors. Increased PGE

Indexed as

Cyclooxygenase 2KidneyReceptors, Prostaglandin E, EP2 SubtypeUreteral ObstructionAnimalsDinoprostoneFibrosisHumansMiceProstaglandins EProstaglandins IRNA, MessengerThromboxanesUp-RegulationUreterCyclooxygenase 2DinoprostoneProstaglandins EProstaglandins IPTGER2 protein, humanPtger2 protein, mousePTGS2 protein, humanPtgs2 protein, mouseReceptors, Prostaglandin E, EP2 SubtypeRNA, MessengerThromboxanesangiogenesishydronephrosisobstructionprostaglandin E2thromboxane

Identifiers

PMID35543087
PMCPMC9542224
OpenAlexW4280625959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.